166 filings
Page 2 of 9
6-K
jzh an3zdkdtpy5h
9 May 23
Current report (foreign)
7:14am
6-K
6fmxic6 sa4crwfgiqed
4 May 23
Current report (foreign)
4:15pm
6-K
49dy9 715wr7q93gn
4 May 23
Galmed Pharmaceuticals forms a Strategic Partnership
4:14pm
6-K
sfonnatg
30 Mar 23
Current report (foreign)
4:27pm
6-K
8q2dy3b6v gsuc
8 Feb 23
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
8:15am
6-K
u4qfiyldd kz
5 Jan 23
Current report (foreign)
4:30pm
6-K
q59a4oq32b u4534
4 Jan 23
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
8:11am
6-K
lmb 67k3w1
14 Dec 22
Current report (foreign)
5:08pm
6-K
m5qkh89mbbzvn9 4nib
16 Nov 22
Current report (foreign)
5:00pm
6-K
7pm58qm5
4 Aug 22
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
8:00am
6-K
24xdmcbk 495vrubj7
7 Jul 22
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
8:47am
6-K
b3ua6g op2kyx7pbhpn4
29 Jun 22
Current report (foreign)
4:30pm
6-K
jwza9l2s 5brh89
22 Jun 22
Current report (foreign)
5:00pm
6-K
ggu mpymou1
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
t0vcxq1gslu g6
17 May 22
Current report (foreign)
9:08am
6-K
mevo95emdy
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
x3do0gzvjm7am
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
oxpfhu1vov1x9
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
dw2au2h
28 Apr 22
Current report (foreign)
8:04am
6-K
cadv ixmw
3 Mar 22
Current report (foreign)
5:16pm